FDA Accepts Supplement Application for IMULDOSA by Accord Biopharma
The FDA has accepted the supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord Biopharma.
Asset / Drug
Drug and asset intelligence for IMULDOSA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.